Cargando…
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer
ERBB2 copy number (CN), measured using next-generation sequencing, is a predictive biomarker for trastuzumab efficacy in human epidermal growth factor receptor 2 (HER2)–positive advanced esophagogastric and gastric cancer (AGC). We aimed to investigate the association of ERBB2 amplification and gene...
Autores principales: | Hino, Kaori, Nishina, Tomohiro, Kajiwara, Takeshi, Bando, Hideaki, Nakamura, Maho, Kadowaki, Shigenori, Minashi, Keiko, Yuki, Satoshi, Ohta, Takashi, Hara, Hiroki, Mizukami, Takuro, Moriwaki, Toshikazu, Ohtsubo, Koushiro, Komoda, Masato, Mitani, Seiichiro, Nagashima, Fumio, Kato, Ken, Yamada, Takanobu, Hasegawa, Hiroko, Yamazaki, Kentaro, Yoshino, Takayuki, Hyodo, Ichinosuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384954/ https://www.ncbi.nlm.nih.gov/pubmed/35952320 http://dx.doi.org/10.1200/PO.22.00135 |
Ejemplares similares
-
The Pathoconnectivity Profile of Alzheimer’s Disease: A Morphometric Coalteration Network Analysis
por: Manuello, Jordi, et al.
Publicado: (2018) -
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022) -
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study
por: Hagiwara, Yuya, et al.
Publicado: (2022) -
Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
por: Moriwaki, Toshikazu, et al.
Publicado: (2021) -
A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression
por: Hamano, Yukako, et al.
Publicado: (2018)